Kura Oncology to Participate in Jefferies Global Healthcare Conference
29 Mayo 2024 - 6:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
its participation in Jefferies Global Healthcare Conference. Troy
Wilson, Ph.D., J.D., President and Chief Executive Officer, is
scheduled to participate in a virtual fireside chat at 3:00 p.m. ET
/ 12:00 p.m. PT on June 5, 2024. A live audio webcast of the
fireside chat will be available in the Investors section of Kura’s
website at www.kuraoncology.com, with an archived replay following
the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways.
Ziftomenib, a once-daily, oral drug candidate targeting the
menin-KMT2A protein-protein interaction, has received Breakthrough
Therapy Designation for the treatment of relapsed/refractory (R/R)
NPM1-mutant acute myeloid leukemia (AML). Kura has completed
enrollment in a Phase 2 registration-directed trial of ziftomenib
in NPM1-mutant R/R AML (KOMET-001). The Company is also conducting
a series of clinical trials to evaluate ziftomenib in combination
with current standards of care in NPM1-mutant and KMT2A-rearranged
newly diagnosed and R/R AML. Tipifarnib, a potent and selective
farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2
trial in combination with alpelisib for patients with
PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating
KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial
as a monotherapy and in combination with targeted therapies
(FIT-001). For additional information, please visit Kura’s website
at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President,
Investor Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenAssociate Director,
Corporate Communications & Investor Relations(858)
500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kura Oncology (NASDAQ:KURA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024